News

The FDA granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Oncology social worker Kelly Dyckman, LCSW, shares key strategies for identifying patient distress, demystifying counseling, and managing trauma.

AMH and INHB testing can identify premenopausal patients with HR+/HER2- breast cancer who may safely avoid chemotherapy, sparing unnecessary toxicity.

Duke Blood Cancer Center's Melissa LaMirand, FNP-C, discusses quad therapies, bispecific workflows, and nursing standardization in multiple myeloma.

Emily M. Beard, BSN, RN, OCN, CBCN, BHCN, discusses the vital role of oncology nurse navigation in addressing barriers to care and improving outcomes in cancer survivorship.

FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses patient compliance, side effect management, and screening anxiety in breast cancer care.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

FDA approves Tudriqev with nivolumab for advanced cutaneous melanoma. Learn about dosing, safety warnings, and trial data for oncology nurses.

Explore how brain cancer-related fatigue impacts patient identity and learn practical person-centered care strategies for nurses and doctors.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

New research shows high-dose oral vitamin D provides rapid relief for chemo-induced erythema and radiation dermatitis without toxicity.

Oncology nurses must differentiate cyclospora from treatment side effects and use PCR-based GI panels to ensure rapid diagnosis during the outbreak.

Oncology nurse Pattie Jakel shares her story of ILC recurrence, highlighting why MRI and specialized education are vital for lobular breast cancer.

A study of 400,000 Medicare beneficiaries finds that while genomic testing is rising, next-generation sequencing remains underutilized in cancer care.

Laura Cullen DNP, RN, FAAN discusses leadership and systems infrastructure ahead of her keynote at the Roswell Park Evidence-Based Practice Symposium.

Michelle Mollica, PhD, RN, discusses training oncology nurses to manage information overload and guide patients post-diagnosis.

FDA approves Pluvicto with ARPI for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer based on rPFS data.

Handa Oncology received FDA tentative approval for Omcazio capsules, a novel cabozantinib formulation with improved absorption and no food effects.

Learn how supportive culture and connection can improve oncology nurse retention and address burnout, shifting focus from individual responsibility.

Fumiko Chino, MD, discusses strategies for oncology nurses to address unproven treatments like ivermectin while maintaining patient trust.

Learn how healthcare teams can support young adults with cancer as they navigate dating, disclosure, body image, and setting boundaries.

Sunny Pharmtech recalls three lots of Cyclophosphamide for Injection after steel particulates were found, posing risks of thromboembolic events.

A nurse shares her story of balancing 12-hour shifts, pregnancy, and a life-changing lymphoma diagnosis in this From the Floor installment.

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

The FDA has approved perioperative pembrolizumab and enfortumab vedotin for adult patients with muscle-invasive bladder cancer.